Turning high potential into high performance.

We are a specialist venture investor with a focus on science and technology companies that are posed for rapid growth.

We invest in sectors where innovation is driving exponential growth, and global demand.

We invest in companies with breakthrough technologies & strong leadership, who are on the cusp of a significant value inflection event.

We deploy the capital, resource and expertise required to mitigate risk and accelerate commercial success.

Our Investment Philosophy

Deploy Smart Capital Focused on Value Creation, Syndication and Global Exit.

The UK develops some of the most advanced and innovative technologies in the world, especially in cutting-edge sectors such as life sciences, Al and robotics. However, many of these technologies fail to demonstrate their true commercial potential due to a scarcity of capital, experience, and resources during early commercialisation stages.

We believe that significant value can be created by investing at this stage, if the appropriate expertise, resources and network can be deployed to nurture the SME through to commercial success.

Guided by a highly experienced investment committee and leading scientific advisory board, NCL have deployed over $55M into the health sector, as a lead investor, over the last 3 years.

Our Portfolio

More than 20 investments in breakthrough technology companies in sectors as diverse as therapeutics, digital health and cleantech.

All Digital Health Medical Technologies Non-Healthcare Therapeutics
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo
Client's company logo

Our Ecosystem

We believe that early-stage, high potential SMEs will benefit immensely from a physical cluster of like-minded entrepreneurs and organisations.

Slider image Slider image Slider image

Our premier life science cluster is Discovery Park, the ex-Pfizer R&D site that has attracted over a hundred high-potential SMEs. The Park has not only premium office facilities and comprehensive service providers on site, but also cutting-edge laboratory facilities that are normally hard to access for small companies. These facilities are always open to our investee companies when needed, with room to scale up as the companies grow.

Our Team

Our team spans three generations and is vastly experienced in venture investment, fund structuring, entrepreneurship and business management and is supported by an expert Scientific Advisory Board.

All Board of Directors International Investment Team Scientific Advisory Board Support Team
Jerry Biggs's headshot

Jerry Biggs

CEO View Profile
Emma Sugrue's headshot

Emma Sugrue

Executive Assistant View Profile
Jonathan Synett's headshot

Jonathan Synett

CIO View Profile
Katerina Sanchez Schilling's headshot

Katerina Sanchez Schilling

Investment Manager View Profile
Nicholas Ibery's headshot

Nicholas Ibery

Sector Expert and Venture Partner, Member of the IC View Profile
Maria Konovalova's headshot

Maria Konovalova

Investment Analyst View Profile
Pat O’Neill's headshot

Pat O’Neill

President - US Operations View Profile
Alan Walker's headshot

Alan Walker

CTO View Profile
Kish Mistry's headshot

Kish Mistry

Senior Analyst View Profile
Graham Hutchins's headshot

Graham Hutchins

Operations Director View Profile
Chris Phillips's headshot

Chris Phillips

Chairman View Profile
Jon Scott-Maxwell's headshot

Jon Scott-Maxwell

Non-Executive Director View Profile
Martin Thorp's headshot

Martin Thorp

Non-Executive Director View Profile
Professor Clive Page's headshot

Professor Clive Page

View Profile
Michelle Garrett's headshot

Michelle Garrett

View Profile
Dr. Mike Westby's headshot

Dr. Mike Westby

View Profile
Martin Riley's headshot

Martin Riley

View Profile
Dr. Greg Bailey's headshot

Dr. Greg Bailey

View Profile

Our News

The child who inspired Andiamo – London’s most exciting tech firm

The agony suffered by tragic Diamo Parvez motivated parents Samiya and Naveed to alleviate the suffering of others through the use of an array … Continued

Read more

These face-reading glasses track physical and mental health

David Vintiner Surgeon Charles Nduka has developed sensor tech to track facial expressions and is currently using it with patients with Parkinson’s. His next … Continued

Read more

New pharma Azadyne raises £1.5m for autoimmune disease treatment

Trinity College’s new spin-out organisation, Azadyne, has completed a £1.5million funding round for its new approach to the treatment of autoimmune diseases. The Kent … Continued

Read more

Want to discuss an investment opportunity with us?

Submit an Opportunity